Free Investing

ChinaBio Today submits: Among the news surfacing from China life science last week, there were four stories that involved relationships between Western life science companies and China, underlying the ongoing theme of a growing interdependence.MDRNA, Inc. (NSDQ: MRNA) announced an RNAi cancer collaboration with AstraZeneca (AZN) Investment (China) Company that is being carried out at AstraZeneca’s Innovation Center in Shanghai (see story). MDRNA’s RNA interference technology combines two proteins to simultaneously inhibit two processes. In the AstraZeneca collaboration, the formulation is being tested as a treatment for liver cancer. Complete Story »

Joseph Krueger submits: At the 28th annual JP Morgan Healthcare conference, which ran from January 11- January 14th 2010, there were more than 300 companies represented, making their presentations to more than 6000 public and private equity and venture capital investors.Leading up to the conference and early last week there was bullish movement in many companies presenting at the conference. Many of the many of the larger companies like Amgen (AMGN), Genzyme (GENZ), Biogen (BIIB), Celgene (CELG), Gilead Sciences (GILD), TEVA Pharmaceuticals TEVA), Watson Pharmaceuticals (WPI) and OSI Pharmaceuticals (OSIP) previewed 2009 earnings during the conference.Complete Story »